US Nuclear Corp

US Nuclear’s All-Purpose CBRN DroneRAD Up 777% in 2019

Los Angeles, CA. June 18, 2019 – In just the first two quarters of 2019, US Nuclear’s (OTC: UCLE) DroneRAD sales are up 777% overall DroneRAD sales for 2018, and based on promised new orders, may soar even higher. Due to new advances, USN drones are now outfitted with a complete CBRN package, chemical, biological, radiation, and nuclear sensing technology.

In addition to detecting radiation, such as radioactive gamma hot-spots or airborne particulates, the DroneRAD is also outfitted with chemical detectors and bacterial/viral collection filters. A proprietary quick-release connector on the DroneRAD allows the operator to quickly change between sensor packages to eliminate downtime, and a special air sampling system allows the chemicals, particulates, and microbes to be collected in-flight without being disrupted by the flight turbulence.

End-users for the DroneRAD include first responders, border security, military, homeland defense, NATO military, waste disposal, oil and gas, chemical plants, nuclear power plants, and many more.

Chemical Detection: The DroneRAD supports multiple chemical sensors at once, and includes the following list: VOC, Carbon Dioxide, Ammonia, Carbon Monoxide, Chlorine, Formaldehyde, Hydrogen, Hydrogen Sulfide, Hydrogen Cyanide, Nitric Oxide, Nitrogen Dioxide, Oxygen, Sulfur Dioxide, Methane, and more.

Biological/Viral Collection: Utilizing special viral and bacterial filters, the DroneRAD collects these microbes and other matter at up to 99.99% efficiency. Postflight, the biological filters are sent to a laboratory for in-depth analysis. Microbes of interest may be anthrax, botulism, plague, staph, e-Coli, cholera, salmonella, listeria, typhus, and others.

GPS and Mapping: All measurable data, such as chemical or radioactive concentration, is GPS tagged and logged/wirelessly sent back to the operator for real-time display. The data is overlaid on Google Earth Maps in real-time, so the operator can immediately see a color-coded visual map of where and when the drone flew, and what the concentration is at each point.

US Nuclear Signs Agreement to Acquire an Interest in a Leading Fusion Power Developer & Rights to Manufacture & Sell Fusion Power Generators for Electric Power Grid

Los Angeles, CA.  April 23, 2019 – US Nuclear Corp. (OTC-UCLE) and Magneto-Inertial Fusion Technologies, Inc. (MIFTI) have now signed an agreement which grants US Nuclear 500,000 shares of Magneto-Inertial Fusion Technologies, Inc. (MIFTI) stock, the option to acquire up to 10% (ten percent) of MIFTI, and non-exclusive worldwide rights to manufacture and sell MIFTI’s patented thermonuclear fusion power generator. MIFTI’s fusion power generator can produce clean, baseload electric power for the US and other power grids and wherever small modular electric power sources are needed. The worldwide energy market is estimated to reach $6 trillion by 2030.

Last year, US Nuclear signed a similar agreement with MIFTEC Labs for a revolutionary new way to produce medical radioisotopes from nuclear fusion power that has several cost and safety advantages over the current nuclear fission-based methods.

(more…)

The Desperate Need For Medical Isotopes

Los Angeles, CA. March 18, 2019 – With preparations underway for manufacturing the MIFTEC Z-pinch (ZEBRA) Fusion Medical Isotope Generators, US Nuclear Corp. (OTCBB: UCLE) is one step closer to ending the dire worldwide shortage of medical isotopes.  The federal government is so desperate to find a domestic, stable supply of medical isotopes that they recently awarded over $60 million in funding to 8 projects/companies working on solutions for this demand.  Of these 8 companies, only 3 have timelines to supply medical isotopes in the near future, and of those 3, Magneto-Inertial Fusion Technologies, Inc (MIFTI, parent company to MIFTEC) has the most promising solution.  MIFTEC’s patented fusion-powered medical isotope generator can not only solve the medical isotope shortage, but the revolutionary process also offers numerous advantages to current production methods, including:

• MIFTEC’s process is fueled by a simple isotope of hydrogen from a renewable source: seawater.
  Current production methods of medical isotopes are fission-based nuclear reactors or accelerators that require either highly enriched or low enriched uranium (HEU/LEU) to operate. These methods are costly, multi-step processes that result in nuclear waste byproducts that must be safely contained and stored for hundreds of years while being protected from theft by terrorists.
• Due to the eco-friendly, fusion-based technology, the capital and operational costs are a fraction of that for fission or accelerator technology.  Additionally, medical isotope production costs are up to 50% less than all other current manufacturing processes.
• The device is designed to fit into most hospitals, nuclear medicine clinics, and laboratories.  It is ideal for local, domestic production, and results in a major reduction in transportation and import costs.  Local production also solves the timeline issues of Mo-99’s 66-hour half-life.
• No production limit problem.  Current methods to build a nuclear reactor or accelerator are time-consuming and expensive, and once finally built, these facilities have a maximum production limit.  There is currently around a $5 billion shortfall in medical isotope production. US Nuclear can build MIFTEC’s medical isotope generators in a fraction of the time and cost, with the production line continuing until demand has been filled.